1/8
08:00 am
whwk
Whitehawk Therapeutics Advances to Clinical Stage with IND Clearance for HWK-007 and Announces IND Submission for HWK-016
Low
Report
Whitehawk Therapeutics Advances to Clinical Stage with IND Clearance for HWK-007 and Announces IND Submission for HWK-016
12/30
04:16 pm
whwk
Whitehawk Therapeutics (NASDAQ:WHWK) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Whitehawk Therapeutics (NASDAQ:WHWK) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
12/22
01:38 pm
whwk
Whitehawk Therapeutics (NASDAQ:WHWK) is now covered by analysts at Jones Trading. They set a "buy" rating and a $7.00 price target on the stock.
Low
Report
Whitehawk Therapeutics (NASDAQ:WHWK) is now covered by analysts at Jones Trading. They set a "buy" rating and a $7.00 price target on the stock.
12/16
04:43 pm
whwk
Whitehawk Therapeutics (NASDAQ:WHWK) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
Medium
Report
Whitehawk Therapeutics (NASDAQ:WHWK) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
12/2
03:47 pm
whwk
Whitehawk Therapeutics (NASDAQ:WHWK) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Whitehawk Therapeutics (NASDAQ:WHWK) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
12/1
08:00 am
whwk
Whitehawk Therapeutics Appoints Margaret Dugan, MD, as Chief Medical Officer
Medium
Report
Whitehawk Therapeutics Appoints Margaret Dugan, MD, as Chief Medical Officer
11/26
02:24 pm
whwk
Whitehawk Therapeutics (NASDAQ:WHWK) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Whitehawk Therapeutics (NASDAQ:WHWK) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
11/26
08:37 am
whwk
Whitehawk Therapeutics to Participate in the Piper Sandler 37th Annual Healthcare Conference [Yahoo! Finance]
Medium
Report
Whitehawk Therapeutics to Participate in the Piper Sandler 37th Annual Healthcare Conference [Yahoo! Finance]
11/26
08:00 am
whwk
Whitehawk Therapeutics to Participate in the Piper Sandler 37th Annual Healthcare Conference
Medium
Report
Whitehawk Therapeutics to Participate in the Piper Sandler 37th Annual Healthcare Conference
11/20
01:41 pm
whwk
Whitehawk Therapeutics (NASDAQ:WHWK) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Whitehawk Therapeutics (NASDAQ:WHWK) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
11/11
08:11 am
whwk
Whitehawk Therapeutics to Present at Jefferies Global Healthcare Conference in London [Yahoo! Finance]
Low
Report
Whitehawk Therapeutics to Present at Jefferies Global Healthcare Conference in London [Yahoo! Finance]
11/11
08:00 am
whwk
Whitehawk Therapeutics to Present at Jefferies Global Healthcare Conference in London
Low
Report
Whitehawk Therapeutics to Present at Jefferies Global Healthcare Conference in London
11/6
08:00 am
whwk
Whitehawk Therapeutics Reports Third Quarter 2025 Financial Results and Recent Highlights
Medium
Report
Whitehawk Therapeutics Reports Third Quarter 2025 Financial Results and Recent Highlights
11/1
09:06 am
whwk
Hedge funds investors own a significant stake of 37% in Whitehawk Therapeutics, Inc. (NASDAQ:WHWK) [Yahoo! Finance]
Medium
Report
Hedge funds investors own a significant stake of 37% in Whitehawk Therapeutics, Inc. (NASDAQ:WHWK) [Yahoo! Finance]
11/1
01:04 am
whwk
Whitehawk Therapeutics (NASDAQ:WHWK) was downgraded by analysts at
Wall
Medium
Report
Whitehawk Therapeutics (NASDAQ:WHWK) was downgraded by analysts at
Wall
10/24
12:30 pm
whwk
Whitehawk Therapeutics Presents Real-World Analysis Confirming PTK7 as a Broadly Expressed, Clinically Relevant Target Across Solid Tumors at AACR-NCI-EORTC
Low
Report
Whitehawk Therapeutics Presents Real-World Analysis Confirming PTK7 as a Broadly Expressed, Clinically Relevant Target Across Solid Tumors at AACR-NCI-EORTC
10/24
12:26 pm
whwk
Whitehawk Therapeutics (NASDAQ:WHWK) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Whitehawk Therapeutics (NASDAQ:WHWK) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.